

PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL SEARCHING AUTHORITY

To:
VOSSIUS & PARTNER
Siebertstrasse 4
D-81675 München
GERMANY

EINGEGANGEN
Vossius & Partner
17. Dez. 2004

INVITATION TO PAY ADDITIONAL FEES

(PCT Article 17(3)(a) and Rule 40.1)

REGISTERED MAIL

Frist
bearb.: 14.1.1F lg

Date of mailing
(day/month/year) 15/12/2004

Applicant's or agent's file reference
H2216 PCT S3

7.1. Re+SSP

PAYMENT DUE
within 30 ~~days~~/days
from the above date of mailing

International application No.
PCT/EP2004/009114

International filing date
(day/month/year) 20/07/2004

Applicant

TRANSGENE S.A.

1. This International Searching Authority

- (i) considers that there are 19 (number of) inventions claimed in the international application covered by the claims indicated ~~below~~ on the extra sheet:

and it considers that the international application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated ~~below~~ on the extra sheet:

- (ii) ☒ has carried out a partial international search (see Annex) ☐ will establish the international search report on those parts of the international application which relate to the invention first mentioned in claims Nos.:

see annex

- (iii) will establish the international search report on the other parts of the international application only if, and to the extent to which, additional fees are paid

2. The applicant is hereby **invited**, within the time limit indicated above, to pay the amount indicated below:

EUR 1.550,00 x 18 = EUR 27.900,00
 Fee per additional invention number of additional inventions total amount of additional fees

Or, _____ x _____ = _____

The applicant is informed that, according to Rule 40.2(c), the payment of any additional fee may be made under protest, i.e., a reasoned statement to the effect that the international application complies with the requirement of unity of invention or that the amount of the required additional fee is excessive.

3. ☐ Claim(s) Nos. _____ have been found to be unsearchable under Article 17(2)(b) because of defects under Article 17(2)(a) and therefore have not been included with any invention.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Maria Brandt

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1

claims 1-11,15-41 as far as they relate to any of the
specific combinations of IL-2 with IL-7

Inventions 2-7

claims 1-11,15-41 as far as they relate to any of the
specific combinations of IL-2 with any of
IL-15, IL-18, IL-21, IL-27, IL-31, or IFNgamma

Invention 8

claims 1-11, and 15-41
as far as they relate to fusion proteins comprising IL-7

Invention 9

claims 1-11, and 15-41
as far as they relate to fusion proteins comprising IL-15

Invention 10

claims 1-41
as far as they relate to fusion proteins comprising IL-18

Invention 11

claims 1-11, and 15-41
as far as they relate to fusion proteins comprising IL-21

Invention 12

claims 1-11, and 15-41
as far as they relate to fusion proteins comprising IL-27

Invention 13

claims 1-11, and 15-41
as far as they relate to fusion proteins comprising IL-31

Inventions 14-19

claims 1-11,15-41 as far as they relate to any of the specific combinations of IFNgamma with

- (8.1.) IL-15
- (8.2.) IL-18
- (8.3.) IL-21
- (8.4.) IL-27
- (8.5.) IL-31
- (8.6.) IL-7

The present set of claims lacks unity within the meaning of R. 13.2. PCT.

The unifying concept of the application as filed is a fusion protein comprising two cytokines (claim 1). More specifically claimed are fusion proteins comprising any two of IL-2, IL-7, IL-15, IL-18, IL-21, IL-27, IL-31, and IFN-gamma (claim 7).

The cited prior art (EP158198, Rock et al., EP225579, EP288809, EP816510, W094/21792) discloses several examples of fusion proteins composed of two different cytokines. In view of these documents, the concept of linking two cytokines as required by claim 1 is not new and therefore cannot provide the special technical concept or feature as required by of R. 13.2 PCT.

The technical problem solved by the present application is the provision of further fusion proteins comprising cytokines. The solution are the fusion proteins as defined in the claims. In view of the cited prior art, these further fusion proteins are not linked by common special technical features.

Inventions 1-7 and 14-19, respectively are not linked by special technical features according to R. 13.2. PCT.

Fusion proteins with IL-2 have been known (e.g. IFNg-IL-2, IL-2 - IFNg, IL-2-GM-CSF, IL-2 - IL-6, and IL-2 - IL-2). Therefore, the group of inventions unified by the presence of IL-2 does not meet the requirements of R. 13.2 EPC, and each fusion protein based on IL-2 constitutes an individual invention. Likewise, because IFNg fusion proteins were already known, any further IFNg based fusion protein constitutes an independent invention.

In total there are 19 independent groups of inventions.

1. The present communication is an Annex to the invitation to pay additional fees (Form PCT/ISA/206). It shows the results of the international search established on the parts of the international application which relate to the invention first mentioned in claims Nos.:
- see 'Invitation to pay additional fees'
2. This communication is not the international search report which will be established according to Article 18 and Rule 43.
3. If the applicant does not pay any additional search fees, the information appearing in this communication will be considered as the result of the international search and will be included as such in the international search report.
4. If the applicant pays additional fees, the international search report will contain both the information appearing in this communication and the results of the international search on other parts of the international application for which such fees will have been paid.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 158 198 A (TAKEDA CHEMICAL INDUSTRIES LTD) 16 October 1985 (1985-10-16) ✓✓ the whole document	1,2,5-7, 17-19, 29-31, 34-36
X	ROCK F ET AL: "OVEREXPRESSION AND STRUCTURE-FUNCTION ANALYSIS OF A BIOENGINEERED IL-2/IL-6 CHIMERIC LYMPHOKINE" PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 5, no. 6, September 1992 (1992-09), pages 583-591, XP000983961 ISSN: 0269-2139 abstract ✓✓	1,2,5-7, 17-19, 29-31, 34-36
X	EP 0 225 579 A (SEARLE & CO) ✓✓ 16 June 1987 (1987-06-16) page 8; claim 8	1,2,5-7, 17-19, 29-31, 34-36
X	EP 0 288 809 A (HOECHST AG) ✓✓ 2 November 1988 (1988-11-02) the whole document ----- -/-	1-5

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

**Annex to Form PCT/ISA/206
COMMUNICATION RELATING TO THE RESULTS
OF THE PARTIAL INTERNATIONAL SEARCH**

International Application No
PCT/EP2004/008114

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 816 510 A (TORAY RESEARCH CENTER INC ; TORAY INDUSTRIES (JP)) 7 January 1998 (1998-01-07) the whole document ✓ ✓	1-5
X	WO 94/21792 A (VIAGENE INC) 29 September 1994 (1994-09-29) ✓ ✓	1-9, 15-20, 22, 26-31, 34-36, 38,40 19-23
Y	pages 10,13,29; claims 1,9,11,17	
Y	WO 98/40498 A (SULLIVAN DANIEL M ; US ARMY (US); ANGLADE EDDY (US); CSAKY KARL G (US)) 17 September 1998 (1998-09-17) figure 1 ✓ ✓	19-21
Y	WO 99/36440 A (HAWKINS ROBERT EDWARD ; UNIV BRISTOL (GB); WHITTINGTON HAYLEY ANN (GB)) 22 July 1999 (1999-07-22) claim 27 ✓ ✓	19-21
Y	WO 98/08947 A (US HEALTH) 5 March 1998 (1998-03-05) ✓ ✓ pages 16,19,44	1-11, 15-38, 40,41
Y	KAUFMANN A.M. ET AL: "Comparison of cytokines and CD80 for enhancement of immunogenicity of cervical cancer cells" IMMUNOBIOLOGY, vol. 202, no. 4, October 2000 (2000-10), pages 339-352, XP009040509 GERMANY abstract ✓ ✓	1-9, 15-38, 40,41
Y	KONDO M ET AL.: "Enhancement of Interleukin-2 induced lymphokine-activated killer activity by Interleukin-7 against autologous human renal cell carcinoma" ONCOLOGY, vol. 55, no. 6, November 1998 (1998-11), pages 588-593, XP009040510 SWITZERLAND abstract ✓ ✓ ----- -/--	1-9, 15-38, 40,41

**Annex to Form PCT/ISA/206
COMMUNICATION RELATING TO THE RESULTS
OF THE PARTIAL INTERNATIONAL SEARCH**

International Application No
PCT/EP2004/008114

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>JU D W ET AL: "Adenovirus-mediated combined suicide gene and interleukin-2 gene therapy for the treatment of established tumor and induction of antitumor immunity." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 1998, vol. 124, no. 12, 1998, pages 683-689, XP002307305 ISSN: 0171-5216 abstract</p>	22,23
Y	<p>US 6 552 005 B1 (MILLER C RYAN ET AL) 22 April 2003 (2003-04-22) the whole document</p>	23
Y	<p>WO 93/20849 A (UNIV TEXAS) 28 October 1993 (1993-10-28) cited in the application the whole document</p>	10,11
Y	<p>WO 99/60128 A (LEMBACH KENNETH J ; SHANAFELT ARMEN B (US); JESMOK GARY (US); BAYER AG) 25 November 1999 (1999-11-25) cited in the application the whole document</p>	10,11
Y	<p>SHANAFELT ARMEN B ET AL: "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo" NATURE BIOTECHNOLOGY, vol. 18, no. 11, November 2000 (2000-11), pages 1197-1202, XP002307306 ISSN: 1087-0156 cited in the application the whole document</p>	10,11

Patent Family Annex

Information on patent family members

International Application No

PCT/EP2004/008114

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0158198	A	16-10-1985	WO 8504420 A1	10-10-1985
			EP 0158198 A1	16-10-1985
			JP 60241890 A	30-11-1985
EP 0225579	A	16-06-1987	US 4935233 A	19-06-1990
			AU 599936 B2	02-08-1990
			AU 6585186 A	04-06-1987
			CA 1304024 C	23-06-1992
			DE 3686397 D1	17-09-1992
			DE 3686397 T2	17-12-1992
			EP 0225579 A2	16-06-1987
			JP 2752336 B2	18-05-1998
			JP 7313170 A	05-12-1995
			JP 2759074 B2	28-05-1998
			JP 9118698 A	06-05-1997
			JP 2612854 B2	21-05-1997
			JP 62282593 A	08-12-1987
			US 5114711 A	19-05-1992
			US 6545124 B1	08-04-2003
			ZA 8609090 A	24-02-1988
EP 0288809	A	02-11-1988	DE 3712985 A1	03-11-1988
			AR 242991 A1	30-06-1993
			AT 79135 T	15-08-1992
			AU 613022 B2	25-07-1991
			AU 1466188 A	20-10-1988
			CA 1322157 C	14-09-1993
			DE 3873397 D1	10-09-1992
			DK 209188 A	17-10-1988
			EP 0288809 A1	02-11-1988
			ES 2033981 T3	01-04-1993
			FI 881743 A ,B,	17-10-1988
			GR 3006141 T3	21-06-1993
			HU 47319 A2	28-02-1989
			IE 61574 B1	16-11-1994
			IL 86086 A	24-01-1995
			JP 2667193 B2	27-10-1997
			JP 63301898 A	08-12-1988
			KR 9700187 B1	06-01-1997
			NO 881658 A ,B,	17-10-1988
			NZ 224247 A	26-04-1990
			PH 25327 A	30-04-1991
			PT 87237 A ,B	01-05-1988
			US 5359035 A	25-10-1994
			ZA 8802659 A	14-10-1988
EP 0816510	A	07-01-1998	EP 0816510 A1	07-01-1998
			CA 2213512 A1	03-07-1997
			WO 9723639 A1	03-07-1997
WO 9421792	A	29-09-1994	US 5662896 A	02-09-1997
			AU 6411994 A	11-10-1994
			CA 2158546 A1	29-09-1994
			EP 0689593 A1	03-01-1996
			JP 9503740 T	15-04-1997
			WO 9421792 A2	29-09-1994
			US 6310045 B1	30-10-2001

Patent Family Annex
Information on patent family members

International Application No
PCT/EP2004/008114

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9840498	A	17-09-1998	US	5998598 A	07-12-1999
			AU	6695398 A	29-09-1998
			WO	9840498 A2	17-09-1998
WO 9936440	A	22-07-1999	AU	2173799 A	02-08-1999
			EP	1066327 A2	10-01-2001
			WO	9936440 A2	22-07-1999
WO 9808947	A	05-03-1998	AU	5507098 A	19-03-1998
			WO	9808947 A1	05-03-1998
US 6552005	B1	22-04-2003	US	6599909 B1	29-07-2003
			US	2003148984 A1	07-08-2003
WO 9320849	A	28-10-1993	US	5229109 A	20-07-1993
			AT	226086 T	15-11-2002
			AU	4284393 A	18-11-1993
			CA	2133831 A1	28-10-1993
			DE	69332413 D1	21-11-2002
			DE	69332413 T2	26-06-2003
			EP	0673257 A1	27-09-1995
			JP	7508714 T	28-09-1995
			WO	9320849 A1	28-10-1993
WO 9960128	A	25-11-1999	AU	759697 B2	17-04-2003
			AU	4078499 A	06-12-1999
			BG	104929 A	28-09-2001
			BR	9910504 A	09-01-2001
			CA	2327349 A1	25-11-1999
			CN	1309705 T	22-08-2001
			EP	1076704 A1	21-02-2001
			HU	0101948 A2	28-09-2001
			JP	2002515247 T	28-05-2002
			NO	20005762 A	11-01-2001
			NZ	508098 A	26-09-2003
			PL	344407 A1	05-11-2001
			RU	2235729 C2	10-09-2004
			SI	20643 A	28-02-2002
			SK	17242000 A3	10-07-2001
			TR	200003354 T2	21-03-2001
			WO	9960128 A1	25-11-1999
			US	2004175357 A1	09-09-2004

Important Information

general

- the **claims cannot be changed** at this point in the procedure, the transmitted report is **not** the ISR (see Art. 19 PCT)
- non-payment does not lead to a **loss of rights**, a new procedure will be started on entry into the regional or national phase
- any payments have to be effected **directly** to this ISA (account details on separate sheets), payments to other entities will not be accepted
- in case of a **total of more than 2 inventions** found: when paying please **specify exactly** which claims should be searched
- an **extension of the set time limit** may be granted, however, the total number of days **shall not exceed 45 days** (Rule 40.3 PCT). It has to be requested in writing (preferably faxed) and must be received by this ISA within the first time limit, i.e. 30 days calculating from the date of mailing.

payment by cheque or money transfer:

- the **date of payment** is considered to be the **date the money is booked** in the EPO account
- faxed cheques are not considered to be a valid payment
- only payments in EUR are accepted, no equivalents in other currencies
- payments by **credit card** are **not possible**

payment by deposit account:

- the **date of payment** is considered to be the date that the **authorisation to deduct fees** from the deposit account is **received at the EPO**

***note:** if you don't have a deposit account with the EPO yourself you might want to consider using the account of an associate as a safe and quick way of paying*

payments under protest according to Rule 40 PCT:

- the protest will **not be accepted** without a payment of additional search fee(s)
- the protest has to be **accompanied by a technical reasoning**
- no **protest fee** needs to be paid yet, only additional search fee(s)

Account Details

Euro accounts of the European Patent Organisation

N° 3 338 800 00 (BLZ 700 800 00)

Dresdner Bank

Promenadeplatz 7

D-80273 München

SWIFT Code: DRESDEFF700

~~N° 300 800 (BLZ 700 100 80)~~

Postbank AG

Bayerstr. 49

D-80138 München

BEST AVAILABLE COPY